Anticancer therapy SMRT-ens up: targeting the BCL6-SMRT interaction in B cell lymphoma.
AUTHORS
- PMID: 20385356[PubMed].
ABSTRACT
Transcription factors have proven to be difficult targets for the development of small-molecule drugs. In this issue of Cancer Cell, Cerchietti et al. identify and characterize a specific, small-molecule inhibitor of BCL6, an oncogenic transcriptional repressor, that has high clinical promise for treating diffuse large B cell lymphoma.
Copyright 2010 Elsevier Inc. All rights reserved.
Transcription factors have proven to be difficult targets for the development of small-molecule drugs. In this issue of Cancer Cell, Cerchietti et al. identify and characterize a specific, small-molecule inhibitor of BCL6, an oncogenic transcriptional repressor, that has high clinical promise for treating diffuse large B cell lymphoma.
Copyright 2010 Elsevier Inc. All rights reserved.